Is Your Data Room Complete, or Decision-Ready?
A complete data room can tell you what exists.
It may not tell you what you should believe.
Clinical-stage assets are often valued on more than the evidence already generated. They are valued on assumptions about what that evidence will become: a durable treatment effect, a reproducible responder population, a viable endpoint, broader clinical relevance, or a stronger therapeutic opportunity.
That is where evidence risk can quietly become valuation risk.
The real diligence question is not simply:
“Is the data room complete?”
It is:
“What does the evidence justify believing today, what are we still assuming, and what could change the value of the asset?”
Our latest Evidence Brief explores how sponsors, investors, and potential partners can distinguish core value, conditional value, and emerging option value before those assumptions become embedded in a term sheet.
Read the full Evidence Brief entitled: What the Data Room Should Know Before the Term Sheet
Inside the brief:
• The observation-versus-inference test for any headline result
• What Accelerated Approval outcomes tell diligence teams about evidence maturity
• The Rubix LS core / conditional / option value framework
